A Follow-up Trial to Assess the Persistence of the Immune Response to the Group B Streptococcus Vaccine (GBS-NN/NN2) After a Primary Vaccination of Healthy Pregnant Women, and to Assess Safety, Reactogenicity, and Immunogenicity of the GBS-NN/NN2 Vaccine When Administered During Follow-Up as a 1 Booster Dose During a New Pregnancy

The main objective of the study is to evaluate the persistence of the immunoglobulin G (IgG) antibody responses, specific to Alpha-like protein CN (AlpCN), Ribosomal Protein N (RibN), Alpha-like protein 1N (Alp1N), and Alpha-like protein 2 and 3 (Alp2-3N), after a primary vaccination with GBS-NN/NN2 in all participants.

Start Date07 Mar 2025

Sponsor / Collaborator

MinervaX ApS

NCT06494475

/ Not yet recruitingPhase 2/3

A Randomised, Observer-Blind Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of a Group B Streptococcus Vaccine (GBS-NN/NN2) When 1 Dose is Administered Concomitantly With the Tdap Vaccine in Healthy-non Pregnant Women 18 to 49 Years of Age Compared to When Each Vaccine is Administered Alone

The main objectives of the study are to demonstrate the non-inferiority of the immune response induced by co administered GBS-NN/NN2 and tetanus, diphtheria, and acellular pertussis (Tdap) compared to the separate administration of GBS-NN/NN2 and Tdap, to evaluate the reactogenicity of GBS NN/NN2 when administered alone or in combination with Tdap, and to evaluate the safety of GBS-NN/NN2 when administered alone or in combination with Tdap in terms of serious adverse events (SAEs) and unsolicited adverse events (AEs).

Start Date17 Dec 2024

Sponsor / Collaborator

MinervaX ApS

NCT06280157

/ TerminatedNot Applicable

A Long-term Follow-up Study to Assess the Persistence of Immunoglobin G (IgG) Antibodies to the GBS-NN/NN2 Vaccine After Vaccination With the GBS-NN/NN2 Vaccine in MVX0002 and/or in MVX0003

The goal of this follow-up study is to investigate the persistence of the immune response induced by the GBS-NN/NN2 vaccine in women who have participated in study MVX0002, and/or in study MVX0003 with GBS-NN/NN2 vaccine and received 1, 2 or 3 doses of GBS-NN/NN2. The main question it aims to answer is to determine the persistence of the immune response induced by the GBS-NN/NN2 vaccine by measuring antibody concentrations.
Participants who had received a primary course of GBS-NN/NN2 in Study MVX0002 and/or MVX0003 will be invited to return to have a single yearly blood sample of approximately 10 mL collected 2 to 5 years after the completion of the previous vaccination.

Start Date18 Jan 2024

Sponsor / Collaborator

MinervaX ApS

[+1]

100 Clinical Results associated with GBS vaccine(Minervax ApS)

100 Translational Medicine associated with GBS vaccine(Minervax ApS)

100 Patents (Medical) associated with GBS vaccine(Minervax ApS)

120

Literatures (Medical) associated with GBS vaccine(Minervax ApS)

01 May 2026·JOURNAL OF NUTRITION

Development and Validation of a Nutrient Profiling Model for Shopping Baskets: The Grocery Basket Score Methodology

Article

Author: Hurrell, Richard ; Orts, Javier ; Marcon, Sandro ; Faeh, David ; Windisch, Paul ; Naef, André

BACKGROUND:

Rating a person's diet as a whole, as opposed to rating individual food items, could help better inform consumers about the health value of their diet.

OBJECTIVES:

Our goal was to develop an automated health rating of grocery shopping baskets, based on the nutrient composition of all the food items contained within the basket, and without knowing how many people consume the food items over what period of time. It is envisaged that the rating, or score, can be deployed by retailers on top of existing loyalty or digital shopping basket programs.

METHODS:

We developed a novel model for calculating Grocery Basket Scores (GBS) that uses nutrient energy densities rather than absolute quantities. It was based on self-reported daily food intake from the National Health and Nutrition Examination Survey as well as mortality follow-up data. We conducted a validation against the Alternate Healthy Eating Index (AHEI) as well as the Nutri-Score.

RESULTS:

The nutrient energy density (GBS) model penalized consuming calories from sugar and saturated fats, high salt intake, as well as consuming calories from beverages. Furthermore, a penalty was applied to foods that have a low ratio of protein, vitamin C, or iron relative to the total number of calories. Fiber consumption was rewarded. The model showed a high degree of correlation with the AHEI (Pearson correlation coefficient: 0.62 for the AHEI without the protective effect of moderate alcohol consumption and 0.60 with it) and the Nutri-Score (PCC: -0.60).

CONCLUSIONS:

The proposed nutrient energy density model is aligned with the recommendations formulated in nutritional guidelines, as indicated by a high degree of correlation with the AHEI and Nutri-Score. Long-term use of a GBS from a single or multiple grocery stores could help consumers adhere to dietary guidelines.

31 Dec 2025·ANNALS OF MEDICINE

Maternal group B Streptococcus decreases infant length and alters the early-life microbiome: a prospective cohort study

Article

Author: He, Yan ; Pan, Shilei ; Chen, Muxuan ; Liang, Qijun ; Zhou, Hongwei ; Wang, Qian ; Li, Shanshan ; Yuan, Chunlei ; Li, Xiaocong ; Xie, Hairui ; Fang, Zhencheng ; Qing, Wei

BACKGROUND:

Maternal colonization with Group B Streptococcus (GBS) disrupts the vaginal microbiota, potentially affecting infant microbiota assembly and growth. While the gut microbiota's importance in infant growth is recognized, the specific effects of maternal GBS on growth remain unclear. This study aimed to explore the effects of maternal vaginal GBS during pregnancy on early infant growth, microbiome, and metabolomics.

METHODS:

We recruited and classified 453 pregnant women from southern China into GBS or healthy groups based on GBS vaginal colonization. Their infants were categorized as GBS-exposed or GBS-unexposed groups. We comprehensively analyzed infant growth, gut microbiota, and metabolites during early life, along with maternal vaginal microbiota during pregnancy, using 16S rDNA sequencing and targeted metabolomics.

RESULTS:

GBS-exposed infants exhibited lower length-for-age z-scores (LAZ) than GBS-unexposed infants, especially at 2 months. Altered gut microbiota and metabolites in GBS-exposed infants correlated with growth, mediating the impact of maternal GBS on infant LAZ. Changes in the vaginal microbiota of the GBS group during the third trimester correlated with infant LAZ. Additionally, differences in neonatal gut microbiota, metabolites, and vaginal microbiota during pregnancy were identified between infants with overall LAZ<-1 within 8 months after birth and their counterparts, enhancing the discriminatory power of fundamental data for predicting the occurrence of LAZ<-1 during the first 8 months of life.

CONCLUSIONS:

GBS exposure is associated with decreased infant length growth, with altered microbiota and metabolites potentially mediating the effects of maternal GBS on offspring length growth, offering potential targets for predicting and addressing growth impairment.

01 Nov 2025·JOURNAL OF AFFECTIVE DISORDERS

Associations between green space, and blue space and mental health outcomes in regional Australia: Cross-sectional and longitudinal analyses

Article

Author: Baliunas, Dolly ; Biddle, Stuart J H ; Roba, Hirbo Shore ; Kolbe-Alexander, Tracy

OBJECTIVE:

The aim of this study is to examine the relationships between green, blue, and green-blue space (GBS) with depression or anxiety in regional areas of Australia.

METHODS:

Cross-sectional and longitudinal analyses were conducted using data from Waves 17 and 21 of the HILDA Survey of Australian adults living in regional areas. Self-reported diagnosis of depression or anxiety was assessed at baseline (Wave 17) and follow-up (wave 21). Green space and GBS were quantified as land cover, and blue space as the presence of inland water in residential areas. Generalised estimating equation models assessed association of green space, blue and GBS with prevalent and incident depression or anxiety.

RESULTS:

Among, 5212 participants (mean age 49.12 ± 18.73) years; 53 % female) at baseline, 931 (17.86 %) reported depression or anxiety. The 4-year cumulative incidence of depression or anxiety was 8.03 %. No associations were observed between green space, blue space, or GBS and prevalent depression or anxiety. At follow-up, GBS coverage of ≥41 % was associated with a 37 % lower risk of incident depression or anxiety (OR = 0.63, 95 % CI: 0.42, 0.98). Gender-stratified analyses, blue space was protective for females at baseline (OR = 0.80, 95 % CI: 0.65, 0.98), while green space (OR = 0.35, 95 % CI: 0.15, 0.82) and GBS (OR = 0.32, 95 % CI: 0.14, 0.74) were proactive for males at follow-up.

CONCLUSION:

GBS may reduce the risk of depression or anxiety in regional Australia adults. Blue space may reduce symptoms of depression or anxiety in females, while green space and GBS benefits males over time.

News (Medical) associated with GBS vaccine(Minervax ApS)

15 Apr 2026

·www.biospace.com

MinervaX Strengthens Executive Leadership Team with Two Strategic Appointments as it Advances its Maternal GBS Vaccine Towards Pivotal Trial Initiation

The appointments of Jamila Louahed as CDO and Hans Henrik Chrois Christensen as CFO bring late ‑ stage development, global regulatory and operational expertise as MinervaX enters its next phase of growth Builds on robust Phase II results, paving the way for a registrational trial and advancing efforts to meet the urgent global need for a GBS vaccine COPENHAGEN, Denmark, April 15, 2026 (GLOBE NEWSWIRE) -- MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announces the appointments of Jamila Louahed as Chief Development Officer and Hans Henrik Chrois Christensen as Chief Financial Officer. These appointments strengthen MinervaX’s capabilities as the company advances its novel GBS vaccine toward pivotal trial initiation in the maternal indication and continues to scale its operations. Jamila Louahed joins from GSK, where she held a senior leadership role in Vaccine Research and Development. She brings over 20 years of experience advancing vaccines from discovery through late-stage development and regulatory approval, with a strong track record in global program execution. Hans Henrik Chrois Christensen brings more than two decades of financial leadership in the life science sector. He has served as CFO in both private and public companies, successfully leading financing strategies and M&A transactions, and supporting organizational growth and operational scale-up. Per Fischer, Chief Executive Officer of MinervaX, said: “Jamila and Hans Henrik join us at an important moment for the company as we prepare for the initiation of our pivotal trial. Their combined expertise in vaccine development and financial strategy will strengthen our ability to execute and deliver on our long-term ambitions. We are united in our commitment to advancing a first‑in‑class GBS vaccine that has the potential to prevent life‑threatening infections affecting families worldwide.” Jamila Louahed, incoming Chief Development Officer of MinervaX, commented: “MinervaX is advancing one of the most promising approaches to GBS. The science is robust, the data are strong, and the program is ready for its next stage of development. Contributing to a vaccine with the potential to reshape outcomes for mothers, infants and older adults is a compelling opportunity.” Hans Henrik Chrois Christensen, incoming Chief Financial Officer of MinervaX, remarked: “MinervaX is at a pivotal point, having made solid progress towards starting its Pivotal trial in the maternal indication, supported by strong advisors and internationally renowned investors. Building the financial and operational strength required at this stage is critical to delivering the first approved GBS vaccine to patients worldwide.” These appointments build on a period of strong momentum for MinervaX. The Company has generated encouraging Phase II clinical data from its maternal immunization program, supported by preliminary surrogate markers of efficacy from natural history studies. Its protein‑only vaccine, based on fusions of highly immunogenic domains from the Alpha‑like protein family (AlpN), is designed to provide extremely broad protection against virtually all circulating GBS strains. Alongside its maternal program, MinervaX is also advancing development of its vaccine in older adults, having recently completed Phase I. These achievements, together with increasing global awareness of the significant burden of GBS, underscore the urgency of advancing a safe and effective vaccine into late‑stage trials. Currently, there are no approved vaccines available for GBS, and the disease remains a major global cause of maternal and infant illness, amounting to an estimated 410,000 cases, and 147,000 stillbirths and infant deaths each year. This rising burden highlights the global importance of bringing an effective vaccine to patients as rapidly as possible. For further information, please contact: MinervaX Per Fischer | Chief Executive Officer Email: info@minervax.com Optimum Strategic Communications Zoe Bolt | Vareen Outhonesack | Henry Williams Email: minervax@optimumcomms.com Tel: +44 (0) 203 882 9621 Notes to Editors: About MinervaX MinervaX is a Danish biotechnology company, established in 2010 to develop a prophylactic vaccine against Group B Streptococcus (GBS), based on research from Lund University. MinervaX is developing a GBS vaccine for maternal immunization, and also for vaccination of older/at risk adults. Phase II clinical data from its maternal vaccination program suggest a high efficacy, based on the preliminary surrogate efficacy marker data from a natural history study. MinervaX’s GBS vaccine is a protein-only vaccine based on fusions of highly immunogenic and protective protein domains from selected surface proteins of GBS, the Alpha-like protein family (AIpN). Given the broad distribution of proteins contained in the vaccine on GBS strains globally, it is expected that MinervaX’s GBS vaccine will confer protection against virtually 100% of all GBS isolates. Details of MinervaX’s completed Phase II clinical trials in pregnant people can be found at under the identifiers NCT04596878 and NCT05154578. In addition to pregnant people, MinervaX has also completed a Phase I trial of its novel GBS vaccine in older adults, under identifier NCT05782179.

VaccinePhase 2Phase 1Executive Change

14 Nov 2024

·www.prnewswire.com

Biotech Entrepreneur Veronica Gambillara Fonck Appointed Chair of MinervaX

COPENHAGEN, Denmark, Nov. 14, 2024 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announced the appointment of Veronica Gambillara Fonck as its new Chair of the Board of Directors. Gerd Zettlmeissl, the previous Chair, who was instrumental in the transition of MinervaX from a preclinical-stage company to a well-funded clinical-stage company, has stepped down from his role for personal reasons but will continue to support MinervaX as a senior advisor. Veronica has been a board member of MinervaX since 2022, following an investment by Pureos Bioventures, where she has served as a Partner since 2022. She has over 18 years of experience across the pharma and biotech industry in various operational roles in vaccine development and has been instrumental in building and growing companies. Veronica was the Co-Founder and CEO of LimmaTech Biologics, a company developing vaccines to prevent life-threatening diseases caused by pathogens resistant to antimicrobial treatments, and GlycoEra AG, a biotech company developing medicines for a variety of diseases using its CustomGlycan platform. Per Fischer, Chief Executive Officer of MinervaX, said: "Veronica has been a key member of our board since October 2022 and her extensive vaccine development experience has been invaluable in the progress of our novel, prophylactic vaccine candidate against GBS. Veronica in her new role as Chair will oversee the next important phase of company development as we prepare for Phase III studies with our maternal GBS vaccine. I would like to thank Gerd for his valuable contributions to the success of MinervaX over the past four years, and we are pleased that we will continue to benefit from his vast experience in his new advisory role." Veronica Gambillara, new Chair of the Board of Directors of MinervaX, commented: "I am thrilled to be taking on this role at such a pivotal stage of development for MinervaX as we advance towards Phase III studies with our GBS vaccine in pregnant people and advance our Phase I studies in older adults. GBS remains a significant unmet medical need, and I look forward to working closely with the board and management team to achieve the full potential of our GBS vaccine to prevent these life-threatening infections." Veronica began her career focusing on clinical R&D and international regulation within the MedTech field. In 2009, she moved to GlycoVaxyn, a specialist vaccine biopharmaceutical company where she held roles in clinical, regulatory, and business development. Veronica was a core member of the GlycoVaxyn team responsible for building and contributing to the success of the company in preparation for its acquisition by GSK in 2015 for $190 million. She is also a board member at Memo Therapeutics. The new Chair appointment follows the recently announced manufacturing agreement with Wacker Biotech in September as MinervaX begins establishing commercial manufacturing for its GBS vaccine candidate. GBS is a major global cause of maternal and infant ill health with no approved vaccine available to prevent the rising early and late onset of GBS. The rising number of GBS cases reported globally each year has reached 410,000 with approximately 147,000 stillbirths and infant deaths reported each year, demonstrating the urgent need for an approved GBS vaccine. Notes to Editors: About MinervaX MinervaX is a Danish biotechnology company, established in 2010 to develop a prophylactic vaccine against Group B Streptococcus (GBS), based on research from Lund University. MinervaX is developing a GBS vaccine for maternal immunization, and also for vaccination of older/at risk adults. Phase II clinical data from its maternal vaccination program suggest a high efficacy, based on the preliminary Correlate of Protection data from a natural history study. MinervaX's GBS vaccine is a protein-only vaccine based on fusions of highly immunogenic and protective protein domains from selected surface proteins of GBS, the Alpha-like protein family (AIpN). Given the broad distribution of proteins contained in the vaccine on GBS strains globally, it is expected that MinervaX's GBS vaccine will confer protection against virtually 100% of all GBS isolates. Details of MinervaX's completed Phase II clinical trials in pregnant people can be found at under the identifiers NCT04596878 and NCT05154578. In addition to pregnant people, MinervaX is also pursuing Phase I development of its novel GBS vaccine in older adults, under identifier NCT05782179. SOURCE MinervaX ApS WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VaccinePhase 2Executive ChangePhase 1Acquisition

17 Sep 2024

·pipelinereview.com

MinervaX and Wacker Biotech Announce Manufacturing Collaboration for Prophylactic Vaccine Targeting Group B Streptococcus

COPENHAGEN, Denmark and MUNICH, Germany I September 17, 2024 I MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS) and Wacker Biotech, a contract development and manufacturing organization (CDMO), wholly owned subsidiary of Wacker Chemie AG, today announce a collaboration to manufacture MinervaX’s active protein ingredients of its GBS vaccine. GBS is responsible for nearly 50 percent of all life-threatening infections in newborns. At any given time, some 15-25 percent of the population, including pregnant people are spontaneously colonized with GBS, and during pregnancy they run the risk of transmitting the bacteria to their child in the womb, during birth and/or during the first months of life. GBS colonization may lead to late abortions, premature delivery, or stillbirth and in the newborn child, may result in sepsis, pneumonia or meningitis, all of which carry a significant risk of severe morbidity, long- term disability or death. With no general implemented and fully protective preventative treatment available for GBS, this underlines the unmet medical need of developing and providing a vaccine to prevent adverse pregnancy outcomes and life- threatening infections in infants caused by GBS. Furthermore, older adults and adults with certain co-morbidities such as diabetes or obesity are also at an increased risk of severe GBS infections and form a second population which would benefit from a prophylactic vaccine against this potentially fatal disease. MinervaX’s lead vaccine candidate, is a novel protein-only vaccine, based on fusions of highly immunogenic and proactive protein domains from selected surface proteins of GBS. The company is strongly committed and dedicated to advancing its novel vaccine and has successfully completed two Phase II clinical trials of its maternal vaccine against GBS and is in preparation to commence Phase III clinical trials in this indication. Data from MinervaX’s GBS vaccine is very positive, demonstrating an acceptable safety profile in pregnant people and their infants, with high immunogenicity, leading to functionally active antibodies, with the potential for broad coverage and protection, alleviating the need for excessive use of antibiotics. Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate, alongside performing the technology transfer, process validation and process characterization activities for later commercial manufacturing. Subsequently, Wacker Biotech will perform all key functions critical to ensure stable commercial supply at its site in Amsterdam, The Netherlands. Per Fischer, CEO of MinervaX, said: “GBS can be life-threatening for newborn babies and is linked to over half a million preterm births annually. Following the EUR 54 million financing last year, our team is advancing the development of our novel prophylactic vaccine against GBS for the benefit of all populations at risk, worldwide. Wacker Biotech is a robust manufacturing partner with a strong track record in late clinical and commercial supply and we look forward to collaborating with the team ahead of commencing Phase III studies.” Ronald Eulenberger, Managing Director of Wacker Biotech B.V. in Amsterdam, stated: “With our strong background in E. coli processes, process characterization, and process validation experiences, we at Wacker Biotech are perfectly suited to support MinervaX with its ongoing program for the prevention of invasive GBS disease.” Details of MinervaX’s completed Phase II clinical trials in pregnant people can be found at https://clinicaltrials.gov/ under the identifiers NCT04596878 and NCT05154578. In addition to pregnant people, MinervaX is also pursuing Phase I development of its novel GBS vaccine in older adults, under identifier NCT05782179. Notes to Editors: About MinervaX MinervaX is a Danish biotechnology company, established in 2010 to develop a prophylactic vaccine against Group B Streptococcus (GBS), based on research from Lund University. MinervaX is developing a GBS vaccine for maternal immunization, and also for vaccination of older/at risk adults. Phase II clinical data from its maternal vaccination program suggest a high efficacy, based on the preliminary Correlate of Protection data from a natural history study. MinervaX’s GBS vaccine is a protein-only vaccine based on fusions of highly immunogenic and protective protein domains from selected surface proteins of GBS, the Alpha-like protein family (AIpN). Given the broad distribution of proteins contained in the vaccine on GBS strains globally, it is expected that MinervaX’s GBS vaccine will confer protection against virtually 100% of all GBS isolates. www.minervax.com About Wacker Biotech Wacker Biotech is a full-service contract manufacturer of therapeutic proteins, live biopharmaceutical products (LBPs), plasmid DNA (pDNA), messenger ribonucleic acid (mRNA) and vaccines based on microbial systems. Wacker Biotech’s portfolio extends from strain/process development and analytical testing through to production for clinical and commercial applications. Wacker Biotech operates three GMP-compliant, FDA- and EMA-certified production plants at its Jena and Halle sites in Germany and in Amsterdam in the Netherlands. In addition, Wacker Biotech has had a plant in San Diego (Wacker Biotech US Inc.) since February 2021. Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are wholly owned subsidiaries of Munich-based Wacker Chemie AG. SOURCE: MinervaX

Phase 2VaccinePhase 3Phase 1

100 Deals associated with GBS vaccine(Minervax ApS)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Streptococcal Infections	Phase 3	-	MinervaX ApS	17 Dec 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04596878 (CTgov)	Phase 2	Streptococcal Infections	200	GBS-NN/NN2 (GBS-NN/NN2 in Pregnant Women Living With HIV)	uenvhioqym = hlrygqiphz gylruinbji (dngvpaqnly, dszzfhdvgw - ulejodirgr) View more	-	14 Jul 2026
				GBS-NN/NN2 (GBS-NN/NN2 in Pregnant Women Who do Not Have HIV)	uenvhioqym = sprmggwtnd gylruinbji (dngvpaqnly, xelomxhfmq - mpllhbqqkt) View more
NCT05782179 (CTgov)	Phase 1	Streptococcal Infections	90	alhydrogel+GBS-NN (Healthy Older Adult : GBS-NN/NN2 50 µg)	snxovipqsg = clmhjdgemv zyptgpyprs (ubjmtcupvv, tbqcrkmwme - cxakxtwsor) View more	-	05 Sep 2025
				alhydrogel+GBS-NN (Healthy Older Adult : GBS-NN/NN2 125 µg)	snxovipqsg = lkgovjuykt zyptgpyprs (ubjmtcupvv, dblpfeoeoc - yquwcjjxms) View more
NCT05005247 (CTgov)	Phase 1	Streptococcal Infections	27	MVX0002 (MVX0002 25 μg GBS-NN/NN2)	ufpexvrmiv = mvzkhmvalv kqilzrbidv (cmahmyiqig, rremrijvny - vbobyolzxu) View more	-	10 Oct 2024
				MVX0002 (MVX0002 50 μg GBS-NN/NN2)	ufpexvrmiv = skijcnzrlx kqilzrbidv (cmahmyiqig, dlwxxybttr - brhmtpxehi) View more
NCT03807245 (MVX0002, CTgov)	Phase 1	Streptococcal Infections	60	GBS-NN/NN2 with Alhydrogel® 25 (GBS-NN/NN2 With Alhydrogel® 25)	zzbgjedtsc = zhidpklrgu mqantbshlm (htowyouzhn, tjochrgzwj - ahfsckivdf) View more	-	24 Dec 2020
				GBS-NN/NN2 with Alhydrogel® 50 (GBS-NN/NN2 With Alhydrogel® 50)	zzbgjedtsc = xvtkmlyaou mqantbshlm (htowyouzhn, cyteyqydgx - lbmumcqcqh) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis